Completed PHASE4 INTERVENTIONAL 2-arm NCT01707251

Intravenous Ibuprofen for Laparoscopic Bariatric Surgery

Sponsor: Cumberland Pharmaceuticals

Conditions Obesity

Interventions Intravenous Ibuprofen Saline

Updated 7 times since 2017 Last updated: Sep 2, 2015 Started: Oct 31, 2012 Primary completion: Mar 31, 2015 Completion: Mar 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01707251, this PHASE4 trial focuses on Obesity and remains completed. Sponsored by Cumberland Pharmaceuticals, it has been updated 7 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Oct 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cumberland Pharmaceuticals
Jacobi Medical Center
Sagatech Electronics Inc, Alberta, Canada

Data source: Jacobi Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• The Bronx, United States